This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mutoh, M. Articles by Wakabayashi, K. Search for Related Content PubMed PubMed Citation Articles by Mutoh, M. Articles by Wakabayashi, K.

Involvement of Prostaglandin E Receptor Subtype EP₄ in Colon Carcinogenesis¹

Cancer Prevention Division, National Cancer Center Research Institute, Tokyo 104-0045, Japan [M. M., K. Wat., T. Kit., Y. S., M. T., T. Kaw., T. S., K. Wak.]; Minase Research Institute, Ono Pharmaceutical Co. Ltd., Osaka 618-8585, Japan [K. T., M. K., T. M., K. K., S. O.]; Department of Physiological Chemistry, Faculty of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8315, Japan [Y. S.]; and Department of Pharmacology, Faculty of Medicine, Kyoto University, Kyoto 606-8315, Japan [S. N.]

	ABSTRACT

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Accumulating evidence indicates that overproduction of prostanoids attributable to overexpression of cyclooxygenase-2 (COX-2) plays an important role in colon carcinogenesis. We have shown recently that the prostaglandin (PG) E receptor, EP₁, but not EP₃, is involved in mouse colon carcinogenesis. In line with our previous study, here we examined the role of prostanoid receptors in colon carcinogenesis using six additional lines of knockout mice deficient in prostanoid receptors EP₂, EP₄, DP, FP, IP, or TP. The animals were treated with the colon carcinogen, azoxymethane (AOM), and examined for the development of aberrant crypt foci (ACFs), putative preneoplastic lesions in the colon. Formation of ACFs was decreased only in the EP₄-knockout mice, to 56% of the wild-type level. To confirm these results, we also examined the inhibitory effects of an EP₄-selective antagonist, ONO-AE2-227, in the diet on the formation of AOM-induced colon ACFs in C57BL/6Cr mice and on the development of intestinal polyps in Min mice. ONO-AE2-227 at a dose of 400 ppm reduced the formation of ACFs to 67% of the control level, and intestinal polyp numbers in Min mice receiving 300 ppm were decreased to 69% of the control level. Plating efficiency assays showed that addition of 1.0 µM ONO-AE1-329, an EP₄-selective agonist, resulted in a 1.8-fold increase in the colony number of the human colon cancer cell line, HCA-7, similar to the effect of PGE₂. Moreover, EP₄ mRNA expression was clearly observed in normal colon mucosa and colon tumors in mice. Our previous and present results indicate that PGE₂ contributes to colon carcinogenesis through its actions mediated through EP₁ and EP₄ receptors; therefore, antagonists for these two receptors may be good candidates as chemopreventive agents against colon cancer.

	Introduction

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Clear benefits have been reported with NSAIDs⁴ as chemopreventive agents against colon carcinogenesis (1 , 2) . NSAIDs inhibit arachidonic acid metabolism via actions on COX, a rate-limiting enzyme in the synthesis of PGs, which affect cell proliferation, tumor growth, apoptosis, and immune responsiveness. The presence of two isoforms of COX has been demonstrated—a constitutive enzyme, COX-1, and an inducible enzyme, COX-2—and a number of observations have suggested that increased activity of this latter plays a critical role in colon carcinogenesis (1, 2, 3, 4, 5, 6) . Recently, it was reported that genetic disruption of COX-1, as well as of COX-2, significantly reduces intestinal polyp formation in Min mice having a nonsense mutation in the Apc gene (7) , so that COX-1 is also suggested to be involved in colon carcinogenesis to some extent.

When considering the possible mechanisms for the chemoprevention of colorectal cancer by NSAIDs, account must be taken of possible PG-independent mechanisms. Studies have shown that NSAIDs cause an increase in cellular arachidonic acid and stimulate the production of sphingomyelinase, resulting in hydrolysis of sphingomyelin to ceramide, which promotes apoptosis of tumor cells (8) . Recently, the potential involvement of peroxisome proliferator-activated receptor as a adenomatous polyposis coli-regulated target of NSAIDs in colon cancer was demonstrated (9) . Moreover, NSAIDs can up-regulate the prostate apoptosis response 4 gene, a proapoptotic gene, in human colon carcinoma HCA-7 cells (10) .

On the other hand, the most striking chemopreventive effects of NSAIDs are thought to be attributable to inhibition of COX with a resultant decrease in PG production. However, it is not fully clear what the legitimate molecular target of PGs is. Prostanoids such as PGE₂, PGD₂, PGF₂, PGI₂ and thromboxane A₂ exert their biological actions through binding to eight specific membrane receptors; the four subtypes EP₁ to EP₄ for PGE₂; DP for PGD₂; FP for PGF₂; IP for PGI₂; and TP for thromboxane A₂ (11 , 12) . The recent establishment of mice lacking the genes encoding these receptors (13, 14, 15, 16, 17, 18) has enhanced our understanding of the involvement of prostanoids and their receptors in the development of colon cancer. In previous studies (19 , 20) , we demonstrated that PGE₂ contributes to colon carcinogenesis through its binding to the PGE₂ receptor subtype EP₁, using a genetic approach in EP₁-knockout mice and a pharmacological assessment with the EP₁-selective antagonists, ONO-8711 and ONO-8713. The same approach using EP₃-knockout mice indicated that the deficiency of EP₃ receptor has no effect on colon carcinogenesis (19) .

The present study was conducted to examine the development of ACFs in six additional lines of mice lacking EP₂, EP₄, DP, FP, IP, or TP. Our results indicate a requirement for the EP₄ receptor in ACF formation by AOM. To confirm these data, we also examined the inhibitory effects of an EP₄-selective antagonist on the formation of colon ACFs induced by AOM in C57BL/6Cr mice and on the development of intestinal polyps in Min mice. Moreover, we determined EP₄ mRNA expression in colonic tissues of mice and examined cell proliferative effects of EP₄ receptor activation using an EP₄-selective agonist. On the basis of the results obtained, the role of EP₄ receptor in colon carcinogenesis is discussed.

	Materials and Methods

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Animals.
Male C57BL/6Cr mice were purchased from Japan SLC, Inc. (Shizuoka, Japan) at 5 weeks of age and female C57BL/6J-Min/+ mice (Min mice) from The Jackson Laboratory (Bar Harbor, ME) at 6 weeks of age. The mouse genes encoding each of the six prostanoid receptors, EP₂, EP₄, DP, FP, IP, and TP, were disrupted by a gene knockout method using homologous recombination, as reported previously (13 , 15, 16, 17, 18) . The generated chimeric mice were mated with C57BL/6Cr mice to produce heterozygotes for the respective alleles. The heterozygotes were backcrossed with C57BL/6Cr mice to exclude possible effects of genetic background. The resulting heterozygous male mice were intercrossed, and the F₂ progeny of the wild-type and homozygous mutant mice were used at 9 (EP₂, FP, IP, and TP) or 13 (DP) weeks of age. In the case of the EP₄-knockout mice, chimeric mice were mated to C57BL/6Cr mice, and homozygous mutants were obtained by interbreeding of the resulting agouti offspring. Most EP₄-deficient neonates with 129 x C57BL background become lethargic within 72 h after birth because of a patent ductus arteriosus, and <5% survive and grow normally (16) . We used male EP₄-knockout mice that survived for analysis of ACF formation starting at 7 weeks of age. Genotypes of the knockout mice were confirmed by PCR according to the method described previously (13 , 15, 16, 17, 18) . The animals were housed in plastic cages at 24 ± 2°C and 55% relative humidity with a 12/12-h light/dark cycle. Water and basal diet (AIN-76A; Bio-Serv, Frenchtown, NJ) or experimental diets, with addition of an EP₄-selective antagonist at the indicated concentrations with thorough mixing, prepared every week, were given ad libitum. Body weights and food intake were measured weekly. The experimental protocol was approved by the Institutional Ethics Review Committee for animal experimentation.

AOM-induced ACF Formation in Prostanoid Receptor-Knockout Mice.
EP₂, EP₄, DP, FP, IP, and TP-knockout [EP₂^-/- (male, n = 7), EP₄^-/- (male, n = 10), DP^-/- (female, n = 11), FP^-/- (male, n = 9), IP^-/- (male, n = 10), and TP^-/- (male, n = 11)] mice and counterpart wild-type mice (n = 7–11/group) were treated with AOM (Sigma Chemical Co., St. Louis, MO) at a dose of 10 mg/kg body weight i.p. once a week for 3 weeks. All mice were sacrificed 5 weeks after the first dose of AOM. After laparotomy, the entire colons were resected and filled with 10% neutral buffered formalin and then opened longitudinally from the anus to the cecum. Each was fixed flat between sheets of filter paper in 10% neutral buffered formalin and then stained with 0.2% methylene blue in saline and scored under a light microscope for the number of ACFs/colon, number of ACs/colon, and mean number of ACs/focus according to the procedure of Bird (21) .

The Selective EP₄ Antagonist, ONO-AE2-227.
The selective EP₄ receptor antagonist, ONO-AE2-227, was chemically synthesized at Ono Pharmaceutical Co., Ltd. Receptor binding experiments with this compound were conducted using Chinese hamster ovary cell lines, stably expressing each type of mouse prostanoid receptor. The Ki values were found to be 2.7 nM for the mouse EP₄ receptor and 21 nM for mouse EP₃ receptor. The Ki values for the other receptors, mouse EP₁, EP₂, DP, FP, IP, and TP receptors were >1000 times higher than that for the mouse EP₄ receptor. Analysis of its agonistic and antagonistic actions showed the compound to act as a potent and competitive antagonist to the EP₄ receptor; it inhibited PGE₂ (100 nM)-induced increase in cytosolic cAMP concentration with a median inhibitory concentration of 10 nM. ONO-AE2-227 also acted as a relatively weak antagonist to the EP₃ receptor; it inhibited the PGE₂ (10 nM)-induced increase in cytosolic calcium concentration with an IC₅₀ of 160 nM. Details for the chemical synthesis and biological activities of ONO-AE2-227 will be reported elsewhere. By high performance liquid chromatography, ONO-AE2-227 was confirmed to be stable for at least 4 weeks at ambient temperature in the diet.

Effects of ONO-AE2-227 on Formation of AOM-induced ACF in C57BL/6Cr Mice and Intestinal Polyps in Min Mice.
C57BL/6Cr male mice, 6 weeks of age, were given i.p. injections of AOM or the vehicle, as described in the experiments for the different lines of prostanoid receptor-knockout mice. The mice in the EP₄-selective antagonist-treated groups were fed diets containing 100 or 400 ppm of ONO-AE2-227 starting the day before the first AOM dosing until the end of the experiment at week 5. Numbers of AOM-injected mice were eight for each group, and those for vehicle-injected mice were three for the 400 ppm of experimental diet groups and three for the control diet group. ACF in the colon of mice were assessed as described above.

Groups of 10 female Min mice were fed diet containing ONO-AE2-227 or basal diet from 6 weeks of age until the termination of the experiment 7 weeks thereafter. It is expected that C57BL/6Cr mice are generally much resistant to chemical treatment than Min mice. In addition, the experimental period with Min mice was longer than that of ACF induction in the experiment with C57BL/6Cr. Therefore, the dose of 300 ppm of ONO-AE2-227 was chosen for the experiment. After sacrifice and laparotomy, the entire intestinal tract was resected, filled with 10% neutral buffered formalin, and divided into four sections: the colon and three sections of the small intestine, including the proximal (4 cm from the pylorus ring of stomach), middle (the proximal half of the remainder), and distal parts. These sections were opened longitudinally and fixed flat between sheets of filter paper in 10% neutral buffered formalin, and the numbers and sizes of polyps were determined under a stereoscopic microscope.

Effects of ONO-AE1-329 and PGE₂ on Colony Formation of HCA-7 Cells.
HCA-7 colony 29, a human colon adenocarcinoma cell line, was kindly provided from Dr. Susan Kirkland (Imperial College of Science, Technology and Medicine, London, United Kingdom). The cells were maintained in DMEM supplemented with 10% heat-inactivated FBS (Hyclone Laboratories, Inc., Logan, UT) and antibiotics (100 µg/ml of streptomycin and 100 units/ml of penicillin) at 37°C in 5% CO₂. The numbers of HCA-7 cell colonies were counted as described previously (22) with slight modifications. In brief, HCA-7 cells were plated in 6-cm cell culture dishes at a density of 1000 cells/dish, with DMEM containing 10% FBS. The selective EP₄ receptor agonist, ONO-AE1-329 (23) , or PGE₂ (Cayman Chemical Co., MI) was added daily to selected cells, and the medium was also replaced every day. Cells were incubated for 14 days, and then colonies were visualized by staining with 0.2% methylene blue and counted manually.

Analysis of EP₄ Expression by RT-PCR in Colon Cancer Samples from AOM-treated Mice.
Male C57BL/6J mice (CLEA Japan, Inc., Tokyo, Japan) at 7 weeks of age were i.p. injected with 10 mg/kg body weight of AOM once a week for a total of six times to obtain many colon tumors, as described previously (3) , and sacrificed at 50 weeks after the first injection. Their colons were removed, and one half of each of five colon tumors and five neighboring normal mucosa samples were immediately frozen, stored at -80°C, and used for RT-PCR analyses. The samples were sonicated, and total RNAs were isolated using ISOGEN (Nippon Gene Co., Tokyo, Japan). One-µg aliquots of total RNA were subjected to the reverse transcription reaction using an RNA LA PCR kit (Takara Shuzo Co., Shiga, Japan). Oligonucleotide primers specific for mouse EP₄ (5'-TTCCGCTCGTGGTGCGAGTGTTC-3'; 5'-GAGGTGGTGTCTGCTTGGGTCAG-3') were used for amplification of each mRNA. All PCR reactions were performed in a final volume of 50 µl for 30 cycles. The PCR products were analyzed by 2% agarose gel electrophoresis.

Statistical Analysis.
The data for ACF and polyp formation are expressed as mean ± SE, and their statistical analysis was carried out with the Student’s t test. Differences were considered statistically significant at P < 0.05.

	Results

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
ACF Development in Prostanoid Receptor-Knockout Mice.
To determine which prostanoid receptors might be involved in colon carcinogenesis, we used a short-term in vivo model using ACF formation induced by AOM as the end point. The mean body weights of the AOM-treated EP₄-knockout mice were comparable with those of AOM-treated wild-type mice. No abnormal clinical signs were observed during the course of the experiment, and no change was evident in organ weights including the liver, kidneys, and spleen between the two groups. ACFs were noted in all animals treated with AOM and were located mainly in the distal colon, with fewer numbers in the middle colon and rectum. In wild-type (EP₄^+/+, n = 10) and knockout (EP₄^-/-, n = 10) mice, the numbers of ACFs/colon were 14.6 ± 2.0 and 8.2 ± 1.4 (P < 0.05), and the mean numbers of ACs/focus were 1.5 ± 0.1 and 1.5 ± 0.1, respectively. Thus, the numbers of ACFs per colon in EP₄-knockout mice were significantly reduced to 56% of the wild-type value. Mice treated with saline showed no evidence of ACF formation in either knockout or wild-type mice.

Under the same conditions, the effects of deficiency of EP₂, DP, FP, IP, or TP receptors on formation of ACFs were examined. As with the EP₄-knockout mice, no abnormal changes in body or organ weights were observed in knockout mice compared with wild-type mice, except for a slight increase in spleen weights of IP-knockout mice. There were no significant differences in the numbers of ACFs/colon in EP₂, DP, FP, IP, and TP-knockout mice from those of their wild-type counterparts. Moreover, the mean numbers of ACs/focus in these receptor-knockout mice groups did not differ from those in the wild-type mice. Fig. 1 summarizes the data for the effects of six prostanoid receptor deficiencies on AOM-induced ACF in mice. For reference, the results for EP₁- and EP₃-knockout mice, reported previously (19) , are also included in Fig. 1 .

View larger version (25K): [in this window] [in a new window]   Fig. 1. Numbers of ACFs developing in the colons of prostanoid receptor-knockout mice and their wild-type counterparts after treatment with AOM. EP1, EP2, EP3, EP4, DP, FP, IP, and TP-knockout mice and their respective wild-type mice were treated with AOM, and the numbers of ACFs were scored at 5 weeks after the first dose of AOM. The values (numbers of ACFs/colon) for each knockout mouse group are expressed as percentages of those for their wild-type counterparts. The data for EP1- and EP3-knockout mice are from our previously published work (19) . , wild-type mice; , knockout mice. *, P < 0.05, compared with the wild-type mice.

Suppression of Intestinal Polyp Formation by the EP₄-selective Antagonist in Min Mice.
Administration of ONO-AE2-227 at a dose of 300 ppm in the diet for 7 weeks did not affect the body weights, feeding, or behavior of Min mice. Data for number and distribution of intestinal polyps in the basal diet and ONO-AE2-227 groups are shown in Table 1 . Most polyps were located in the small intestine with only a few in the colon. Administration of ONO-AE2-227 significantly reduced the total number of polyps to 69% of that in the basal diet group. The number of polyps detected in the distal portion of the small intestines was significantly lower (65% of the basal diet group value), and that in the middle portion was also lower (74% of the basal diet group value), although this was not statistically significant. Fig. 2 shows the size distributions of intestinal polyps in the basal diet and ONO-AE2-227-treated groups. Treatment with the EP₄-selective antagonist significantly reduced the number of polyps measuring 1.0 mm in diameter but not those measuring <1.0 mm in diameter.

View larger version (20K): [in this window] [in a new window]   Fig. 2. Size distribution of intestinal polyps in Min mice. , basal diet; , 300 ppm ONO-AE2-227. (The structure is shown in lower part of the figure). Polyps were classified in terms of their diameters in millimeters. The number of polyps/mouse in each size class is expressed as the means; bars, SE. **, P < 0.01, compared with the basal diet group.

View larger version (35K): [in this window] [in a new window]   Fig. 3. HCA-7 colony number in response to treatment with ONO-AE1-329 or PGE2. HCA-7 cells were plated in six-cm cell culture dishes at a density of 1000 cells/dish, with DMEM containing 10% FBS. Cells were incubated for 14 days, and then colonies were visualized by staining with 0.2% methylene blue and counted manually. Data are means (n = 3); bars, SE. Similar results were obtained in three separate experiments.

View larger version (61K): [in this window] [in a new window]   Fig. 4. EP4 receptor expression in normal colon and colon cancer tissues of mice. Aliquots of total RNA (1 µg) from colon cancers and neighboring normal colon tissues were subjected to RT-PCR. The reaction mixture for mouse EP4 was first heated at 94°C for 2 min, followed by amplification for 30 cycles at 95°C for 30 s, 60°C for 45 s, and 72°C for 4 min. These temperatures and time intervals were followed by a final incubation at 72°C for 5 min. The PCR products were separated on 2% agarose gels, and portions corresponding to the expected DNA size (488 bp) of the PCR products are shown in the middle of the figure with an arrow. N, normal mucosa; T, tumor.

	Discussion

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

PGE₂ was earlier suggested to stimulate an increase in cell proliferation and motility of the colon cancer cell line LS-174 by activating the phosphatidylinositol 3-kinase/Akt pathway via EP₄ receptor activation (26) . It is also known that PGE₂ activates adenylate cyclase via a cholera toxin-sensitive, stimulatory G protein through binding to the EP₄ receptor. In the adenylate cyclase pathway, increased cAMP levels result in an activation of cAMP-dependent protein kinase (PKA) and a transcriptional factor that binds to cAMP-responsive elements to transactivate the transcription of specific primary response genes that initiate cell proliferation (27) . These biological changes could contribute to colon carcinogenesis through EP₄ receptor involvement. The EP₁ receptor is a transmembrane G protein-coupled receptor, similar to other PGE₂ receptors, but its signal transduction mechanism is not known in detail. EP₁ signals are transmitted by increased intracellular Ca²⁺ concentrations and activate protein kinase C (11 , 12) . Additional studies are needed to investigate events downstream of the EP₁ receptor signaling pathway and any link between EP₁ and EP₄ receptors. Recently, it was reported that homozygous deletion of the gene encoding EP₂ receptor resulted in decrease of intestinal polyp formation in the Apc knockout mice (28) . These data are not consistent with the results obtained in the present study. Therefore, involvement of EP₂ receptor in AOM-induced colon carcinogenesis in rodents and intestinal polyp formation in Min mice needs to be examined using EP₂ receptor antagonists.

Selective inhibitors of COX-2 are good candidates as chemopreventive agents, with clinically important mechanism-based safety characteristics that significantly distinguish them from traditional NSAIDs, which suffer from gastrointestinal side effects that limit long-term application. It might be expected that these adverse effects are further diminished by inhibiting the downstream of COX pathway. On the basis of the present results, selective EP₁ and/or EP₄ receptor antagonists may be particularly beneficial as chemopreventive agents for colon cancer with low toxicity.

In conclusion, the data obtained in our present and previous studies suggest that PGE₂ mediates colonic carcinogenic changes by acting at EP₁ and EP₄ receptors in the colon. For confirmation, long-term colon carcinogenesis experiments with EP₁ and EP₄ antagonists are currently being conducted in our laboratory.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported in part by a grant from the Organization for Pharmaceutical Safety and Research of Japan, a Grant-in-Aid for Cancer Research and a Grant-in-Aid for the Second-Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labor and Welfare of Japan, and a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, Culture and Technology of Japan.

² These two authors contributed equally to this work.

³ To whom requests for reprints should be addressed, at Cancer Prevention Division, National Cancer Center Research Institute, 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan. Phone: 81-3-3542-2511, extension 4500; E-mail: kwakabay{at}gan2.ncc.go.jp

⁴ The abbreviations used are: NSAID, nonsteroidal anti-inflammatory drug; COX, cyclooxygenase; PG, prostaglandin; ACF, aberrant crypt focus; AOM, azoxymethane; ONO-AE2-227, 2-[2-{2-(1-naphthyl)propanoylamino}phenyl]methylbenzoic acid; ONO-AE1-329, 16-(3-methoxymethyl)phenyl--tetranor-3,7-dithia-PGE₁; cAMP, cyclic AMP; FBS, fetal bovine serum; RT-PCR, reverse transcription-PCR.

Received 9/21/01. Accepted 11/15/01.

	REFERENCES

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 

1. Smalley W. E., DuBois R. N. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv. Pharmacol., 39: 1-20, 1997.
2. Elder D. J. E., Paraskeva C. COX-2 inhibitors for colorectal cancer. Nat. Med., 4: 392-393, 1998.[Medline]
3. Fukutake M., Nakatsugi S., Isoi T., Takahashi M., Ohta T., Mamiya S., Taniguchi Y., Sato H., Fukuda K., Sugimura T., Wakabayashi K. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis (Lond.), 19: 1939-1942, 1998.[Abstract/Free Full Text]
4. Kawamori T., Rao C. V., Seibert K., Reddy B. S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res., 58: 409-412, 1998.[Abstract/Free Full Text]
5. Steinbach G., Lynch P. M., Phillips R. K., Wallace M. H., Hawk E., Gordon G. B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L. K., Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 342: 1946-1952, 2000.[Abstract/Free Full Text]
6. Oshima M., Dinchuk J. E., Kargman S. L., Oshima H., Hancock B., Kwong E., Trzaskos J. M., Evans J. F., Taketo M. M. Suppression of intestinal polyposis in Apc ⁷¹⁶ knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.[Medline]
7. Chulada P. C., Thompson M. B., Mahler J. F., Doyle C. M., Gaul B. W., Lee C., Tiano H. F., Morham S. G., Smithies O., Langenbach R. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res., 60: 4705-4708, 2000.[Abstract/Free Full Text]
8. Chan T. A., Morin P. J., Vogelstein B., Kinzler K. W. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc. Natl. Acad. Sci. USA, 95: 681-686, 1998.[Abstract/Free Full Text]
9. He T. C., Chan T. A., Vogelstein B., Kinzler K. W. PPAR is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell, 99: 335-345, 1999.[Medline]
10. Zhang Z., DuBois R. N. Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. Gastroenterology, 118: 1012-1017, 2000.[Medline]
11. Coleman R. A., Smith W. L., Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev., 46: 205-229, 1994.[Medline]
12. Ushikubi F., Hirata M., Narumiya S. Molecular biology of prostanoid receptors: an overview. J. Lipid Mediat. Cell Signalling, 12: 343-359, 1995.[Medline]
13. Matsuoka T., Hirata M., Tanaka H., Takahashi Y., Murata T., Kabashima K., Sugimoto Y., Kobayashi T., Ushikubi F., Aze Y., Eguchi N., Urade Y., Yoshida N., Kimura K., Mizoguchi A., Honda Y., Nagai H., Narumiya S. Prostaglandin D₂ as a mediator of allergic asthma. Science (Wash. DC), 287: 2013-2017, 2000.[Abstract/Free Full Text]
14. Ushikubi F., Segi E., Sugimoto Y., Murata T., Matsuoka T., Kobayashi T., Hizaki H., Tuboi K., Katsuyama M., Ichikawa A., Tanaka T., Yoshida N., Narumiya S. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP₃. Nature (Lond.), 395: 281-284, 1998.[Medline]
15. Hizaki H., Segi E., Sugimoto Y., Hirose M., Saji T., Ushikubi F., Matsuoka T., Noda Y., Tanaka T., Yoshida N., Narumiya S., Ichikawa A. Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP₂. Proc. Natl. Acad. Sci. USA, 96: 10501-10506, 1999.[Abstract/Free Full Text]
16. Segi E., Sugimoto Y., Yamasaki A., Aze Y., Oida H., Nishimura T., Murata T., Matsuoka T., Ushikubi F., Hirose M., Tanaka T., Yoshida N., Narumiya S., Ichikawa A. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP₄-deficient mice. Biochem. Biophys. Res. Commun., 246: 7-12, 1998.[Medline]
17. Sugimoto Y., Yamasaki A., Segi E., Tsuboi K., Aze Y., Nishimura T., Oida H., Yoshida N., Tanaka T., Katsuyama M., Hasumoto K., Murata T., Hirata M., Ushikubi F., Negishi M., Ichikawa A., Narumiya S. Failure of parturition in mice lacking the prostaglandin F receptor. Science (Wash. DC), 277: 681-683, 1997.[Abstract/Free Full Text]
18. Murata T., Ushikubi F., Matsuoka T., Hirata M., Yamasaki A., Sugimoto Y., Ichikawa A., Aze Y., Tanaka T., Yoshida N., Ueno A., Oh-ishi S., Narumiya S. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature (Lond.), 388: 678-682, 1997.[Medline]
19. Watanabe K., Kawamori T., Nakatsugi S., Ohta T., Ohuchida S., Yamamoto H., Maruyama T., Kondo K., Ushikubi F., Narumiya S., Sugimura T., Wakabayashi K. Role of the prostaglandin E receptor subtype EP₁ in colon carcinogenesis. Cancer Res., 59: 5093-5096, 1999.[Abstract/Free Full Text]
20. Watanabe K., Kawamori T., Nakatsugi S., Ohta T., Ohuchida S., Yamamoto H., Maruyama T., Kondo K., Narumiya S., Sugimura T., Wakabayashi K. Inhibitory effect of a prostaglandin E receptor subtype EP₁ selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice. Cancer Lett., 156: 57-61, 2000.[Medline]
21. Bird R. P. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett., 37: 147-151, 1987.[Medline]
22. Sheng H., Shao J., Morrow J. D., Beauchamp R. D., DuBois R. N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E₂ in human colon cancer cells. Cancer Res., 58: 362-366, 1998.[Abstract/Free Full Text]
23. Yamane H., Sugimoto Y., Tanaka S., Ichikawa A. Prostaglandin E₂ receptors, EP₂ and EP₄, differentially modulate TNF- and IL-6 production induced by lipopolysaccharide in mouse peritoneal neutrophils. Biochem. Biophys. Res. Commun., 278: 224-228, 2000.[Medline]
24. Morimoto K., Sugimoto Y., Katsuyama M., Oida H., Tsuboi K., Kishi K., Kinoshita Y., Negishi M., Chiba T., Narumiya S., Ichikawa A. Cellular localization of mRNAs for prostaglandin E receptor subtypes in the mouse gastrointestinal tract. Am. J. Physiol, 272: G681-G687, 1997.[Abstract/Free Full Text]
25. Rigas B., Goldman I. S., Levine L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med., 122: 518-523, 1993.[Medline]
26. Sheng H., Shao J., Washington M. K., DuBois R. N. Prostaglandin E₂ increases growth and motility of colorectal carcinoma cells. J. Biol. Chem., 276: 18075-18081, 2001.[Abstract/Free Full Text]
27. Dhanasekaran N., Tsim S. T., Dermott J. M., Onesime D. Regulation of cell proliferation by G proteins. Oncogene, 17: 1383-1394, 1998.[Medline]
28. Sonoshita M., Takaku K., Sasaki N., Sugimoto Y., Ushikubi F., Narumiya S., Oshima M., Taketo M. M. Acceleration of intestinal polyposis through prostaglandin receptor EP₂ in Apc⁷¹⁶ knockout mice. Nat. Med., 7: 1048-1051, 2001.[Medline]

This article has been cited by other articles:

				M.-R. Pan, M.-F. Hou, H.-C. Chang, and W.-C. Hung Cyclooxygenase-2 Up-regulates CCR7 via EP2/EP4 Receptor Signaling Pathways to Enhance Lymphatic Invasion of Breast Cancer Cells J. Biol. Chem., April 25, 2008; 283(17): 11155 - 11163. [Abstract] [Full Text] [PDF]

				K. M. Ansari, Y. M. Sung, G. He, and S. M. Fischer Prostaglandin receptor EP2 is responsible for cyclooxygenase-2 induction by prostaglandin E2 in mouse skin Carcinogenesis, October 1, 2007; 28(10): 2063 - 2068. [Abstract] [Full Text] [PDF]

				M. Misikangas, A.-M. Pajari, E. Paivarinta, S. I. Oikarinen, J. Rajakangas, M. Marttinen, H. Tanayama, R. Torronen, and M. Mutanen Three Nordic Berries Inhibit Intestinal Tumorigenesis in Multiple Intestinal Neoplasia/+ Mice by Modulating {beta}-Catenin Signaling in the Tumor and Transcription in the Mucosa J. Nutr., October 1, 2007; 137(10): 2285 - 2290. [Abstract] [Full Text] [PDF]

				V. Blanc, J. O. Henderson, R. D. Newberry, Y. Xie, S.-J. Cho, E. P. Newberry, S. Kennedy, D. C. Rubin, H. L. Wang, J. Luo, et al. Deletion of the AU-Rich RNA Binding Protein Apobec-1 Reduces Intestinal Tumor Burden in Apcmin Mice Cancer Res., September 15, 2007; 67(18): 8565 - 8573. [Abstract] [Full Text] [PDF]

				S. Donnini, F. Finetti, R. Solito, E. Terzuoli, A. Sacchetti, L. Morbidelli, P. Patrignani, and M. Ziche EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways FASEB J, August 1, 2007; 21(10): 2418 - 2430. [Abstract] [Full Text] [PDF]

				Y. Sugimoto and S. Narumiya Prostaglandin E Receptors J. Biol. Chem., April 20, 2007; 282(16): 11613 - 11617. [Abstract] [Full Text] [PDF]

				S. Han, J. D. Ritzenthaler, B. Wingerd, H. N. Rivera, and J. Roman Extracellular Matrix Fibronectin Increases Prostaglandin E2 Receptor Subtype EP4 in Lung Carcinoma Cells through Multiple Signaling Pathways: THE ROLE OF AP-2 J. Biol. Chem., March 16, 2007; 282(11): 7961 - 7972. [Abstract] [Full Text] [PDF]

				H. Makita, M. Mutoh, T. Maruyama, K. Yonemoto, A. Kobayashi, H. Fujitsuka, M. Toida, T. Shibata, S. Miyamoto, Y. Yasui, et al. A prostaglandin E2 receptor subtype EP1-selective antagonist, ONO-8711, suppresses 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis Carcinogenesis, March 1, 2007; 28(3): 677 - 684. [Abstract] [Full Text] [PDF]

				J. M. Park, Y. Kanaoka, N. Eguchi, K. Aritake, S. Grujic, A. M. Materi, V. S. Buslon, B. L. Tippin, A. M. Kwong, E. Salido, et al. Hematopoietic Prostaglandin D Synthase Suppresses Intestinal Adenomas in ApcMin/+ Mice Cancer Res., February 1, 2007; 67(3): 881 - 889. [Abstract] [Full Text] [PDF]

				S. Swami, A. V. Krishnan, J. Moreno, R. B. Bhattacharyya, D. M. Peehl, and D. Feldman Calcitriol and Genistein Actions to Inhibit the Prostaglandin Pathway: Potential Combination Therapy to Treat Prostate Cancer J. Nutr., January 1, 2007; 137(1): 205S - 210S. [Abstract] [Full Text] [PDF]

				A. M. Fulton, X. Ma, and N. Kundu Targeting Prostaglandin E EP Receptors to Inhibit Metastasis. Cancer Res., October 15, 2006; 66(20): 9794 - 9797. [Abstract] [Full Text] [PDF]

				L. Yang, Y. Huang, R. Porta, K. Yanagisawa, A. Gonzalez, E. Segi, D. H. Johnson, S. Narumiya, and D. P. Carbone Host and Direct Antitumor Effects and Profound Reduction in Tumor Metastasis with Selective EP4 Receptor Antagonism Cancer Res., October 1, 2006; 66(19): 9665 - 9672. [Abstract] [Full Text] [PDF]

				O. K. Glebov, L. M. Rodriguez, P. Lynch, S. Patterson, H. Lynch, K. Nakahara, J. Jenkins, J. Cliatt, C.-J. Humbyrd, J. DeNobile, et al. Celecoxib treatment alters the gene expression profile of normal colonic mucosa. Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1382 - 1391. [Abstract] [Full Text] [PDF]

				M. Muller, K. J. Sales, A. A. Katz, and H. N. Jabbour Seminal Plasma Promotes the Expression of Tumorigenic and Angiogenic Genes in Cervical Adenocarcinoma Cells via the E-Series Prostanoid 4 Receptor Endocrinology, July 1, 2006; 147(7): 3356 - 3365. [Abstract] [Full Text] [PDF]

				T. Payner, H. A. Leaver, B. Knapp, I. R. Whittle, O. C. Trifan, S. Miller, and M. T. Rizzo Microsomal prostaglandin E synthase-1 regulates human glioma cell growth via prostaglandin E2-dependent activation of type II protein kinase A. Mol. Cancer Ther., July 1, 2006; 5(7): 1817 - 1826. [Abstract] [Full Text] [PDF]

				O. Schroder, Y. Yudina, A. Sabirsh, N. Zahn, J. Z. Haeggstrom, and J. Stein 15-deoxy-{Delta}12,14-prostaglandin J2 inhibits the expression of microsomal prostaglandin E synthase type 2 in colon cancer cells J. Lipid Res., May 1, 2006; 47(5): 1071 - 1080. [Abstract] [Full Text] [PDF]

				D. J. Kim, K.S. Prabhu, F. J. Gonzalez, and J. M. Peters Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-{beta}/{delta} (PPAR{beta}/{delta}) Carcinogenesis, May 1, 2006; 27(5): 1105 - 1112. [Abstract] [Full Text] [PDF]

				J.-Y. Qian, A. Leung, P. Harding, and M. C. LaPointe PGE2 stimulates human brain natriuretic peptide expression via EP4 and p42/44 MAPK Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1740 - H1746. [Abstract] [Full Text] [PDF]

				X. Ma, N. Kundu, S. Rifat, T. Walser, and A. M. Fulton Prostaglandin E Receptor EP4 Antagonism Inhibits Breast Cancer Metastasis. Cancer Res., March 15, 2006; 66(6): 2923 - 2927. [Abstract] [Full Text] [PDF]

				S. D. Chell, I. R. Witherden, R. R. Dobson, M. Moorghen, A. A. Herman, D. Qualtrough, A. C. Williams, and C. Paraskeva Increased EP4 Receptor Expression in Colorectal Cancer Progression Promotes Cell Growth and Anchorage Independence. Cancer Res., March 15, 2006; 66(6): 3106 - 3113. [Abstract] [Full Text] [PDF]

				M. Mutoh, T. Akasu, M. Takahashi, N. Niho, T. Yoshida, T. Sugimura, and K. Wakabayashi Possible Involvement of Hyperlipidemia in Increasing Risk of Colorectal Tumor Development in Human Familial Adenomatous Polyposis Jpn. J. Clin. Oncol., March 1, 2006; 36(3): 166 - 171. [Abstract] [Full Text] [PDF]

				G. D'Orazi, M. G. Sciulli, V. Di Stefano, S. Riccioni, M. Frattini, R. Falcioni, L. Bertario, A. Sacchi, and P. Patrignani Homeodomain-Interacting Protein Kinase-2 Restrains Cytosolic Phospholipase A2-Dependent Prostaglandin E2 Generation in Human Colorectal Cancer Cells Clin. Cancer Res., February 1, 2006; 12(3): 735 - 741. [Abstract] [Full Text] [PDF]

				T. Otani, K. Yamaguchi, E. Scherl, B. Du, H.-H. Tai, M. Greifer, L. Petrovic, T. Daikoku, S. K. Dey, K. Subbaramaiah, et al. Levels of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-{alpha} Am J Physiol Gastrointest Liver Physiol, February 1, 2006; 290(2): G361 - G368. [Abstract] [Full Text] [PDF]

				D Wang and R N DuBois PROSTAGLANDINS AND CANCER Gut, January 1, 2006; 55(1): 115 - 122. [Full Text] [PDF]

				H A Patsos, D J Hicks, R R H Dobson, A Greenhough, N Woodman, J D Lane, A C Williams, and C Paraskeva The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2 Gut, December 1, 2005; 54(12): 1741 - 1750. [Abstract] [Full Text] [PDF]

				Y. Shoji, M. Takahashi, N. Takasuka, N. Niho, T. Kitamura, H. Sato, T. Maruyama, Y. Sugimoto, S. Narumiya, T. Sugimura, et al. Prostaglandin E receptor EP3 deficiency modifies tumor outcome in mouse two-stage skin carcinogenesis Carcinogenesis, December 1, 2005; 26(12): 2116 - 2122. [Abstract] [Full Text] [PDF]